PortalPublikationenExternal Beam Radiotherapy Affects Serum Testosterone in Pat...

External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer

Standard

External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. / Pompe, Raisa S; Karakiewicz, Pierre I; Zaffuto, Emanuele; Smith, Ariane; Bandini, Marco; Marchioni, Michele; Tian, Zhe; Leyh-Bannurah, Sami-Ramzi; Schiffmann, Jonas; Delouya, Guila; Lambert, Carole; Bahary, Jean-Paul; Beauchemin, Marie Claude; Barkati, Maroie; Ménard, Cynthia; Graefen, Markus; Saad, Fred; Tilki, Derya; Taussky, Daniel.

in: J SEX MED, Jahrgang 14, Nr. 7, 07.2017, S. 876-882.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pompe, RS, Karakiewicz, PI, Zaffuto, E, Smith, A, Bandini, M, Marchioni, M, Tian, Z, Leyh-Bannurah, S-R, Schiffmann, J, Delouya, G, Lambert, C, Bahary, J-P, Beauchemin, MC, Barkati, M, Ménard, C, Graefen, M, Saad, F, Tilki, D & Taussky, D 2017, 'External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer', J SEX MED, Jg. 14, Nr. 7, S. 876-882. https://doi.org/10.1016/j.jsxm.2017.04.675

APA

Pompe, R. S., Karakiewicz, P. I., Zaffuto, E., Smith, A., Bandini, M., Marchioni, M., Tian, Z., Leyh-Bannurah, S-R., Schiffmann, J., Delouya, G., Lambert, C., Bahary, J-P., Beauchemin, M. C., Barkati, M., Ménard, C., Graefen, M., Saad, F., Tilki, D., & Taussky, D. (2017). External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. J SEX MED, 14(7), 876-882. https://doi.org/10.1016/j.jsxm.2017.04.675

Vancouver

Pompe RS, Karakiewicz PI, Zaffuto E, Smith A, Bandini M, Marchioni M et al. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. J SEX MED. 2017 Jul;14(7):876-882. https://doi.org/10.1016/j.jsxm.2017.04.675

Bibtex

@article{34e9c5042dd141bc8ce6e9501a4881d1,
title = "External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer",
abstract = "BACKGROUND: Previous studies have examined testosterone levels after external beam radiation (EBRT) monotherapy, but since 2002 only sparse contemporary data have been reported.AIM: To examine testosterone kinetics in a large series of contemporary patients after EBRT.METHODS: The study was conducted in 425 patients who underwent definitive EBRT for localized prostate cancer from 2002 through 2014. Patients were enrolled in several phase II and III trials. Exclusion criteria were neoadjuvant or adjuvant androgen-deprivation therapy or missing data. Testosterone was recorded at baseline and then according to each study protocol (not mandatory in all protocols). Statistical analyses consisted of means and proportions, Kaplan-Meier plots, and logistic and Cox regression analyses.OUTCOMES: Testosterone kinetics after EBRT monotherapy and their influence on biochemical recurrence.RESULTS: Median follow-up of 248 assessable patients was 72 months. One hundred eighty-six patients (75.0%) showed a decrease in testosterone. Median time to first decrease was 6.4 months. Median percentage of decrease to the nadir was 30% and 112 (45.2%) developed biochemical hypogonadism (serum testosterone < 8 nmol/L). Of all patients with testosterone decrease, 117 (62.9%) recovered to at least 90% of baseline levels. Advanced age, increased body mass index, higher baseline testosterone level, and lower nadir level were associated with a lower chance of testosterone recovery. Subgroup analyses of 166 patients treated with intensity-modulated radiotherapy confirmed the results recorded for the entire cohort. In survival analyses, neither testosterone decrease nor recovery was predictive for biochemical recurrence.CLINICAL IMPLICATIONS: EBRT monotherapy influences testosterone kinetics, and although most patients will recover, approximately 45% will have biochemical hypogonadism.STRENGTHS AND LIMITATIONS: We report on the largest contemporary series of patients treated with EBRT monotherapy in whom testosterone kinetics were ascertained. Limitations are that testosterone follow-up was not uniform and the study lacked information on health-related quality-of-life data.CONCLUSION: Our findings indicate that up to 75% of patients will have a profound testosterone decrease, with up to a 40% increase in rates of biochemical hypogonadism, although the latter events will leave biochemical recurrence unaffected. Pompe RS, Karakrewicz PI, Zaffuto E, et al. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. J Sex Med 2017;14:876-882.",
keywords = "Aged, Humans, Hypogonadism, Male, Prostate-Specific Antigen, Prostatic Neoplasms, Radiotherapy, Testosterone, Treatment Outcome, Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article",
author = "Pompe, {Raisa S} and Karakiewicz, {Pierre I} and Emanuele Zaffuto and Ariane Smith and Marco Bandini and Michele Marchioni and Zhe Tian and Sami-Ramzi Leyh-Bannurah and Jonas Schiffmann and Guila Delouya and Carole Lambert and Jean-Paul Bahary and Beauchemin, {Marie Claude} and Maroie Barkati and Cynthia M{\'e}nard and Markus Graefen and Fred Saad and Derya Tilki and Daniel Taussky",
note = "Copyright {\textcopyright} 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = jul,
doi = "10.1016/j.jsxm.2017.04.675",
language = "English",
volume = "14",
pages = "876--882",
journal = "J SEX MED",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer

AU - Pompe, Raisa S

AU - Karakiewicz, Pierre I

AU - Zaffuto, Emanuele

AU - Smith, Ariane

AU - Bandini, Marco

AU - Marchioni, Michele

AU - Tian, Zhe

AU - Leyh-Bannurah, Sami-Ramzi

AU - Schiffmann, Jonas

AU - Delouya, Guila

AU - Lambert, Carole

AU - Bahary, Jean-Paul

AU - Beauchemin, Marie Claude

AU - Barkati, Maroie

AU - Ménard, Cynthia

AU - Graefen, Markus

AU - Saad, Fred

AU - Tilki, Derya

AU - Taussky, Daniel

N1 - Copyright © 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

PY - 2017/7

Y1 - 2017/7

N2 - BACKGROUND: Previous studies have examined testosterone levels after external beam radiation (EBRT) monotherapy, but since 2002 only sparse contemporary data have been reported.AIM: To examine testosterone kinetics in a large series of contemporary patients after EBRT.METHODS: The study was conducted in 425 patients who underwent definitive EBRT for localized prostate cancer from 2002 through 2014. Patients were enrolled in several phase II and III trials. Exclusion criteria were neoadjuvant or adjuvant androgen-deprivation therapy or missing data. Testosterone was recorded at baseline and then according to each study protocol (not mandatory in all protocols). Statistical analyses consisted of means and proportions, Kaplan-Meier plots, and logistic and Cox regression analyses.OUTCOMES: Testosterone kinetics after EBRT monotherapy and their influence on biochemical recurrence.RESULTS: Median follow-up of 248 assessable patients was 72 months. One hundred eighty-six patients (75.0%) showed a decrease in testosterone. Median time to first decrease was 6.4 months. Median percentage of decrease to the nadir was 30% and 112 (45.2%) developed biochemical hypogonadism (serum testosterone < 8 nmol/L). Of all patients with testosterone decrease, 117 (62.9%) recovered to at least 90% of baseline levels. Advanced age, increased body mass index, higher baseline testosterone level, and lower nadir level were associated with a lower chance of testosterone recovery. Subgroup analyses of 166 patients treated with intensity-modulated radiotherapy confirmed the results recorded for the entire cohort. In survival analyses, neither testosterone decrease nor recovery was predictive for biochemical recurrence.CLINICAL IMPLICATIONS: EBRT monotherapy influences testosterone kinetics, and although most patients will recover, approximately 45% will have biochemical hypogonadism.STRENGTHS AND LIMITATIONS: We report on the largest contemporary series of patients treated with EBRT monotherapy in whom testosterone kinetics were ascertained. Limitations are that testosterone follow-up was not uniform and the study lacked information on health-related quality-of-life data.CONCLUSION: Our findings indicate that up to 75% of patients will have a profound testosterone decrease, with up to a 40% increase in rates of biochemical hypogonadism, although the latter events will leave biochemical recurrence unaffected. Pompe RS, Karakrewicz PI, Zaffuto E, et al. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. J Sex Med 2017;14:876-882.

AB - BACKGROUND: Previous studies have examined testosterone levels after external beam radiation (EBRT) monotherapy, but since 2002 only sparse contemporary data have been reported.AIM: To examine testosterone kinetics in a large series of contemporary patients after EBRT.METHODS: The study was conducted in 425 patients who underwent definitive EBRT for localized prostate cancer from 2002 through 2014. Patients were enrolled in several phase II and III trials. Exclusion criteria were neoadjuvant or adjuvant androgen-deprivation therapy or missing data. Testosterone was recorded at baseline and then according to each study protocol (not mandatory in all protocols). Statistical analyses consisted of means and proportions, Kaplan-Meier plots, and logistic and Cox regression analyses.OUTCOMES: Testosterone kinetics after EBRT monotherapy and their influence on biochemical recurrence.RESULTS: Median follow-up of 248 assessable patients was 72 months. One hundred eighty-six patients (75.0%) showed a decrease in testosterone. Median time to first decrease was 6.4 months. Median percentage of decrease to the nadir was 30% and 112 (45.2%) developed biochemical hypogonadism (serum testosterone < 8 nmol/L). Of all patients with testosterone decrease, 117 (62.9%) recovered to at least 90% of baseline levels. Advanced age, increased body mass index, higher baseline testosterone level, and lower nadir level were associated with a lower chance of testosterone recovery. Subgroup analyses of 166 patients treated with intensity-modulated radiotherapy confirmed the results recorded for the entire cohort. In survival analyses, neither testosterone decrease nor recovery was predictive for biochemical recurrence.CLINICAL IMPLICATIONS: EBRT monotherapy influences testosterone kinetics, and although most patients will recover, approximately 45% will have biochemical hypogonadism.STRENGTHS AND LIMITATIONS: We report on the largest contemporary series of patients treated with EBRT monotherapy in whom testosterone kinetics were ascertained. Limitations are that testosterone follow-up was not uniform and the study lacked information on health-related quality-of-life data.CONCLUSION: Our findings indicate that up to 75% of patients will have a profound testosterone decrease, with up to a 40% increase in rates of biochemical hypogonadism, although the latter events will leave biochemical recurrence unaffected. Pompe RS, Karakrewicz PI, Zaffuto E, et al. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. J Sex Med 2017;14:876-882.

KW - Aged

KW - Humans

KW - Hypogonadism

KW - Male

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Radiotherapy

KW - Testosterone

KW - Treatment Outcome

KW - Clinical Trial, Phase II

KW - Clinical Trial, Phase III

KW - Journal Article

U2 - 10.1016/j.jsxm.2017.04.675

DO - 10.1016/j.jsxm.2017.04.675

M3 - SCORING: Journal article

C2 - 28546065

VL - 14

SP - 876

EP - 882

JO - J SEX MED

JF - J SEX MED

SN - 1743-6095

IS - 7

ER -